Acumen Pharmaceuticals(ABOS)
Focus: Acumen Pharmaceuticals is a newly public (2024) biotech company focused on developing Alzheimer's disease therapeutics, specifically targeting antibody-based approaches. The company operates at micro-cap scale with under 50 employees.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
1
Should You Work at Acumen Pharmaceuticals?
AI assessmentHigh-risk, high-reward early-stage opportunity best suited for scientists/operators comfortable with biotech volatility and willing to build infrastructure from scratch.
Why Work Here
- Early-stage opportunity to shape a company going public in 2024 with focused Alzheimer's franchise in high-unmet-need space
- Direct exposure to Phase 2 asset (sabirnetug) with potential for rapid advancement given AD market tailwinds
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACU193
Alzheimer DiseaseClinical Trials (2)
NCT04931459A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
Phase 1Help build intelligence for Acumen Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.